G3BP1: A Drug Target / Disease Biomarker (G10146)

Target Name: G3BP1

NCBI ID: G10146

G3BP1

G3BP1: A Drug Target / Disease Biomarker

G3BP1, also known as UCP2 or NEDD8, is a protein that plays a critical role in cellular processes such as metabolism, inflammation, and stress response. It has also been identified as a potential drug target and biomarker for various diseases, including obesity, type 2 diabetes, and neurodegenerative disorders.

G3BP1 is a key player in the UCP2 complex, a protein complex that plays a central role in the regulation of energy metabolism and the effects of stress in cells. The UCP2 complex is composed of UCP2, UCP4, UCP5, and UCP6, and it is responsible for the catalytic activity of UCP2, which is a critical enzyme for the transfer of electrons in the cell's energy budget.

G3BP1 functions as a negative regulator of UCP2, which means that it works to reduce the activity of UCP2 and limit its effects on energy metabolism and stress response. This is accomplished through a variety of mechanisms, including the formation of a covalent complex with UCP2, the inhibition of UCP2 activity by G3BP1 itself, and the regulation of UCP2 expression and activity by other proteins.

G3BP1's role in energy metabolism is multifaceted and includes the regulation of cellular energy homeostasis, the control of cellular stress response, and the modulation of cellular signaling pathways. It is well established that G3BP1 plays a critical role in the regulation of abdominal obesity, a major risk factor for various diseases, including obesity, type 2 diabetes, and cardiovascular disease.

G3BP1 has also been identified as a potential biomarker for several diseases, including obesity, type 2 diabetes, and neurodegenerative disorders. For example, studies have shown that G3BP1 levels are elevated in individuals with obesity and are associated with an increased risk of developing type 2 diabetes. Additionally, G3BP1 has been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

G3BP1 is also a potential drug target for these diseases, as several studies have shown that inhibiting G3BP1 activity can improve insulin sensitivity, reduce inflammation, and improve overall health and lifespan in individuals with obesity and type 2 diabetes. Additionally, G3BP1 inhibition has been shown to improve the cognitive function and reduce the neurotoxicity of several common neurodegenerative drugs in animal models.

In conclusion, G3BP1 is a protein that plays a critical role in energy metabolism and stress response. It is a potential drug target and biomarker for various diseases, including obesity, type 2 diabetes, and neurodegenerative disorders. Further research is needed to fully understand the role of G3BP1 in these diseases and to develop effective therapies that target this protein.

Protein Name: G3BP Stress Granule Assembly Factor 1

Functions: ATP- and magnesium-dependent helicase that plays an essential role in innate immunity (PubMed:30510222). Participates in the DNA-triggered cGAS/STING pathway by promoting the DNA binding and activation of CGAS. Enhances also RIGI-induced type I interferon production probably by helping RIGI at sensing pathogenic RNA (PubMed:30804210). In addition, plays an essential role in stress granule formation (PubMed:12642610, PubMed:20180778, PubMed:23279204). Unwinds preferentially partial DNA and RNA duplexes having a 17 bp annealed portion and either a hanging 3' tail or hanging tails at both 5'- and 3'-ends (PubMed:9889278). Unwinds DNA/DNA, RNA/DNA, and RNA/RNA substrates with comparable efficiency (PubMed:9889278). Acts unidirectionally by moving in the 5' to 3' direction along the bound single-stranded DNA (PubMed:9889278). Phosphorylation-dependent sequence-specific endoribonuclease in vitro (PubMed:11604510). Cleaves exclusively between cytosine and adenine and cleaves MYC mRNA preferentially at the 3'-UTR (PubMed:11604510)

The "G3BP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about G3BP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets